A multi-arm trial investigating HS-110 in combination with other immunotherapies in patients with non-small cell lung cancer
Phase of Trial: Phase III
Latest Information Update: 07 Dec 2017
At a glance
- Drugs Viagenpumatucel-L (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- 07 Dec 2017 According to a Heat Biologics media release, the company has received written responses from the U.S. Food and Drug Administration (FDA) following its Type C meeting regarding the clinical trial design. Trial design details and next steps are expected to be announced in 2H 2018.
- 05 Feb 2015 New trial record
- 02 Feb 2015 According to a Heat Biologics media release, this trial is expected to start in the first half of 2015.